Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study by Bowen, Joanne M et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
‘This is the peer reviewed version of the following 
article: Bowen J, White I, Tsykin A, Smith L, Kristaly K, 
Thompson SK, Karapetis CS, Tan H, Game PA, Irvine T, 
Hussey DJ, Watson DI, Keefe D. Pre-therapy mRNA 
expression of TNF is associated with treatment-induced 
gastrointestinal toxicity in patients with esophageal 
cancer: A pilot study. Supportive Care in Cancer (2015) 
23:3165-3172.
which has been published in final form at 
DOI:
http://dx.doi.org/10.1007/s00520-015-2696-7
Copyright (2015) © Springer-Verlag Berlin 
Heidelberg 
1	  
Title page 1	  
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in 2	  
patients with esophageal cancer: A pilot study 3	  
Bowen JM1, White I2, Smith L3, Tsykin A4, Kristaly K2, Thompson SK3, Karapetis CS5, Tan H6, 4	  
Game PA3, Irvine T7, Hussey DJ7, Watson DI7, Keefe DMK25	  
1. School of Medical Sciences, University of Adelaide, 2. School of Medicine, University of 6	  
Adelaide, 3. Discipline of Surgery, University of Adelaide, 4. Centre for Cancer Biology, SA 7	  
Pathology, 5. School of Medicine, Flinders University, 6. RAH Cancer Centre, Royal Adelaide 8	  
Hospital, 7. Department of Surgery, Flinders University, Adelaide, South Australia, Australia. 9	  
Address for correspondence: 10	  
Dr Joanne M Bowen 11	  
School of Medical Sciences 12	  
University of Adelaide 13	  
From Rd, Adelaide 5005, SA 14	  
Australia 15	  
T: +618 83131374 16	  
F: +618 8313 5384 17	  




Purpose: Esophageal cancer has a high mortality rate, and its multimodality treatment is often 2	  
associated with significant rates of severe toxicity.   Effort is needed to uncover ways to maximize 3	  
effectiveness of therapy through identification of predictive markers of response and toxicity. As 4	  
such, the aim of this study was to identify genes predictive of chemoradiotherapy-induced 5	  
gastrointestinal toxicity using an immune pathway-targeted approach. 6	  
Methods: Adults with esophageal cancer treated with chemotherapy consisting of 5-fluorouracil and 7	  
cisplatin, and 45-50 Gy radiation were recruited to the study.  Pre-therapy-collected whole blood was 8	  
analyzed for relative expression of immune genes using RT-PCR.  Gene expression was compared 9	  
between patients who experienced severe regimen-related gastrointestinal toxicity vs. those 10	  
experiencing mild to moderate toxicity. 11	  
Results: Blood from 31 patients were analyzed by RT-PCR. Out of 84 immune genes investigated, 12	  
TNF was significantly elevated (2.05-fold, p = 0.025) in the toxic group (n = 12) compared to the 13	  
non-toxic group (n = 19). Nausea and vomiting was the most commonly documented severe toxicity. 14	  
No associations between toxicity and response, age, sex, histology or treatment were evident.  15	  
Conclusions: This study supports evidence of TNF as a predictive biomarker in regimen-related 16	  
gastrointestinal toxicity. Confirming these findings in a larger cohort is warranted.  17	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Introduction 1	  
Across the past four decades, the incidence of esophageal adenocarcinoma (EAC) has increased 6-2	  
fold throughout the Western World, particularly in men, whilst rates of squamous cell carcinoma 3	  
(SCC) of the esophagus remain unchanged [1].  Esophageal cancer has one of the poorest survival 4	  
rates among patients with solid tumors, and its multimodality treatment with combined chemotherapy 5	  
and radiotherapy is often associated with significant rates of severe toxicity [2, 3].   Effort is needed to 6	  
uncover ways to maximize the effectiveness of therapy through identification of predictive markers of 7	  
response and toxicity.   8	  
Acute toxicity affecting the gastrointestinal (GI) mucosa is a major impediment to optimal cancer 9	  
treatment and is particularly problematic in cancers of the esophagus.  Patients with locally advanced 10	  
tumors are typically managed with neoadjuvant or definitive chemoradiotherapy (CRT) [4, 5], which 11	  
results in up to 43% of patients experiencing severe (grade ≥ 3) GI toxicity (including oral mucositis, 12	  
esophagitis, nausea and vomiting and diarrhea) depending on the protocol [6].  Of significant clinical 13	  
importance, GI toxicity can lead to up to 45% of patients not receiving full dose chemotherapy, and 14	  
up to 30% having interrupted radiotherapy [3, 7], and this can negatively impact on treatment success. 15	  
Complete pathological response to CRT is associated with better long term survival [8].  However, 16	  
25% of patients do not respond to CRT and hence undergo this treatment and its toxicities 17	  
unnecessarily [9].   18	  
Reliable predictive markers of severe GI toxicity risk are currently unavailable.  One potential 19	  
approach is the use of gene expression signatures [10-12].  Numerous lines of evidence support the 20	  
role of basal gene expression in establishing a pre-treatment risk profile, and a number of studies have 21	  
found associations between genetic factors and regimen-related toxicity [13-15].  Recently, attention 22	  
has moved away from pharmacogenetic risk gene such as dihydropyrimidine dehydrogenase (DPYD) 23	  
due to the rarity of informative variants and consequent failure to account for the majority of toxicity 24	  
seen [16]. Instead, increased focus has been placed on the role of immune determinants of mucosal 25	  
inflammation.  This is borne out of the knowledge that GI toxicity (most notably mucositis) is 26	  
4	  
	  
fundamentally underpinned by mucosal inflammatory damage.  Substantial preclinical and clinical 1	  
research has shown that many of the key mediators of regimen related mucosal injury are derived 2	  
from the innate immune response pathway [17]. In particular, activation of the transcription factor 3	  
NF-κB, and up-regulation of its pro-inflammatory cytokine target genes including TNF-α, IL-1β and 4	  
IL-6 are implicated in modulating injury [18, 19]. Furthermore, the severity of mucosal injury 5	  
correlates with the intensity of pro-inflammatory cytokine production, and interference with cytokine 6	  
production favorably modifies the course of experimental mucositis [20]. In clinical studies, increased 7	  
levels of TNF-α and IL-6 measured in peripheral blood correlates with mucositis severity [21, 22]. 8	  
These findings implicate pro-inflammatory cytokines as central medicators in the pathogenesis of 9	  
cancer therapy-induced GI toxicity and promote their further investigation as risk modifiers. In 10	  
support of observations from mRNA and animal models, genetic variants in mucosal injury mediators, 11	  
such as TNF-α, NF-κB, IL-1β and IL-6, have been linked to toxicity [13, 23, 24].  12	  
Based on these previous studies, we hypothesized that pre-therapy expression of innate immune genes 13	  
would be measurably different in patients that go on to suffer from severe GI toxicity compared to 14	  
those that do not.  As such, this proof of concept pilot study used an immune pathway-targeted, multi-15	  
array approach to prospectively analyze pre-therapy gene expression profiles in patients with 16	  




Patient identification and sample collection 2	  
This study was approved by the Royal Adelaide Hospital Research Ethics Committee and complied 3	  
with the Declaration of Helsinki.  All study participants gave written informed consent.  Eligible 4	  
participants were identified at the South Australian Statewide Upper Gastrointestinal Cancer 5	  
Multidisciplinary Team Meeting or by endoscopy surgical lists, and approached for inclusion at the 6	  
hospital or by mailed study information sheets.  Patients with cancer of the esophagus (including 7	  
adenocarcinoma, squamous cell carcinoma and gastroesophageal junction) scheduled to receive 8	  
concurrent CRT were eligible for inclusion.  Chemotherapy entailed 2 cycles of 5-fluorouracil (1000 9	  
mg/m2/day for 96 h by ambulatory pump) and cisplatin (75 mg/m2) spaced 4 weeks apart. Radiation 10	  
consisted of 45 Gy, if given before surgical resection, and 50 Gy if given as definitive treatment, 11	  
administered as 25 equal fractions across 5 weeks. Pretreatment supportive medication was standard 12	  
and consisted of 165mg aprepitant, 12mg dexamethasone and 10mg ondansetron / 250mcg 13	  
palonosetron.  Post infusion medication included 165mg aprepitant, 10-20mg metoclopramide (as 14	  
required for nausea), 8mg dexamethasone (2 tablets daily x 3 days) and 2-4mg loperamide (as 15	  
required for diarrhea). Patients who had received prior chemotherapy or radiation, had a serious 16	  
concomitant medical or psychiatric illness, or had active mucosal ulceration were excluded.  Patients 17	  
were prospectively recruited and gave 2.5 mL of blood, collected into PaxGene RNA tubes for 18	  
stabilization of RNA (PreAnalytiX, Qiagen) prior to therapy.   19	  
Clinical records were reviewed for collection of clinical information, including patient demographics, 20	  
chemotherapy and radiation protocol, tumor histology, and toxicity.  Two specialist esophageal 21	  
surgeons independently reviewed the clinical records to determine response to CRT, as summarized in 22	  
table 1. All toxicity data was graded according to the National Cancer Institute Common Terminology 23	  
Criteria for Adverse Events version 4.0.   To maintain uniformity, a single investigator [IW] was 24	  
responsible for data extraction and final toxicity scoring as directed by physician reporting in case 25	  
notes.  For the purpose of analysis, patients were categorized as either toxic or non-toxic.  Patients 26	  
6	  
	  
with any reported GI toxicity grade ≥3 were assigned as toxic, whereas patients with grade ≤2 toxicity 1	  
were assigned as “non-toxic”.  Any patient that required a dose reduction, treatment break or 2	  
hospitalization due to GI toxicity was automatically assigned to the toxic group.  The Fisher’s exact 3	  
test was used to compare patient characteristics between groups. 4	  
RNA isolation  5	  
Total RNA was isolated from whole blood using the PreAnalytiX RNA extraction kit as per 6	  
manufacturers’ instructions (Qiagen, CA, USA).  Briefly, silica-membrane spin column technology is 7	  
used, where RNA >18 nucleotides (including miRNA) binds to the membrane, is subjected to DNase 8	  
digestion to remove genomic DNA contamination and washed before final elution in proprietary 9	  
buffer solution.  Integrity of eluted RNA was tested with the Agilent Bioanalyzer at the Adelaide 10	  
Microarray Centre (University of Adelaide).  11	  
PCR arrays and RT-PCR 12	  
The RT² Profiler™ PCR Array Human Innate & Adaptive Immune Responses in 100 disk format 13	  
(Qiagen, CA, USA) was used to compare relative transcript expression between groups.  All arrays 14	  
were conducted according to manufacturers’ instructions, including cDNA synthesis using the RT2 15	  
HT First Strand Kit, and use of SYBR Green ROX FAST Mastermix for the Rotor-Gene cycler.  16	  
Cycle threshold values were analyzed by 2-∆∆CT to determine expression fold changes and unpaired t-17	  
test used to detect significance between groups, respectively. 18	  
For real-time polymerase chain reaction (RT-PCR) validation of differentially expressed transcripts, 19	  
RNA was converted to cDNA using the iScript cDNA synthesis kit (Biorad, CA, USA) as per 20	  
manufacturers’ instructions.  Primers were purchased from Qiagen (QuantiTect Primer Assays) with 21	  
expression normalized to housekeeping gene, UBC, which has been extensively used in our laboratory 22	  
[25], although not present on the PCR array.  All RT-PCR reactions contained 1 µl (10 ng) cDNA, 5 23	  
µl Sybr Green, 3 µl RNase-free water and 1 µl of primer mix.  Using the Rotor-Gene Q (Qiagen, CA, 24	  
USA) each run consisted of 40 cycles; 95°C (15 seconds), 55°C (30 seconds) and 72°C (30 seconds).  25	  
7	  
	  
Cycle threshold cutoff was set whilst viewing fluorescent readings in log scale.  A melt curve analysis 1	  
was conducted to ensure amplification of specific products.  Normalized expression values were 2	  
assessed by Wilcoxon Sign Rank test, with a p value of <0.05 considered significant. 3	  




Patient Toxicity  2	  
Between December 2009 and March 2013 a total of 31 blood samples were collected from eligible 3	  
patients (Figure 1).  These were classified as toxic (n = 12) or non-toxic (n= 19) and included in the 4	  
molecular analysis (Full description in supplementary table 1).  Patients were well balanced across the 5	  
two groups for age, tumor histology, clinical stage and treatment (Table 2).  Grade ≥3 nausea or 6	  
vomiting occurred in 8/31 (26%) patients, making it the most common severe GI toxicity 7	  
documented.  This was as expected given that the regimen is highly emetogenic.  All GI toxicities that 8	  
occurred with frequency of 10% or greater are shown in Table 3.      9	  
PCR array 10	  
Initially, RNA from 4 toxic and 4 non-toxic patients was compared in the PCR array analysis which 11	  
included 84 innate and adaptive immune response genes, and 5 housekeeping genes.  A filter was 12	  
applied so that genes with less than 75% detection rate (3 out of 4 arrays in each group) were 13	  
classified as absent.  This limit resulted in 25 genes being excluded from analysis (Supplementary 14	  
table 2).  Three housekeeping genes were stable and used for normalization; B2M (-1.11-fold), ACTB 15	  
(-1.05-fold) and GAPDH (1.17-fold).  Two housekeeping genes, RPL13A and HPRT1, were excluded 16	  
due to a significant difference in expression (average CT value difference greater than 2) between the 17	  
two groups.  Three innate immunity genes were significantly upregulated in the toxic group compared 18	  
to the non-toxic group; NFKB1 (1.67-fold, p = 0.01), IL1B (2.19-fold, p = 0.029) and TNF (2.14-fold, 19	  
p = 0.042). No genes were significantly downregulated in the toxic group.  20	  
RT-PCR validation 21	  
The three genes identified as significantly upregulated by PCR array were then investigated in all 22	  
toxic and non-toxic samples by semi-quantitative RT-PCR.  TNF expression was significantly 23	  
increased in the toxic group (2.05-fold, p = 0.025), whereas IL1B and NFKB1expression was similar 24	  
between groups (Figure 2).  The housekeeping gene, UBC, was stable (-1.27-fold).     25	  
9	  
	  
Response to CRT 1	  
Response data was available 29 patients. Complete or near complete response was 31%, partial 2	  
response (including minimal, moderate, good partial and poor partial) was 62%, and poor or no 3	  
response was 7%.  Severe GI toxicity was not associated with the response of the tumor to CRT 4	  




GI toxicity is a collection of adverse effects of cancer treatment that seriously impact on patient 2	  
quality of life and treatment compliance.  This study included the most commonly experienced acute 3	  
GI symptoms associated with 5-FU, cisplatin and radiation therapy, namely nausea and vomiting, 4	  
diarrhea and mucositis/esophagitis [3, 6, 7], to uncover genes that would act as pre-therapy predictive 5	  
markers of GI toxicity.  We found that severe GI toxicity occurred frequently within our cohort, with 6	  
39% of patients experiencing at least one of the symptoms at a severe level within the first cycle of 7	  
treatment.  Importantly, each of the GI toxicity symptoms occurred within the wide range of 8	  
frequency expected for the regimen [3].   Most patients did not experience toxicities singularly, but 9	  
rather two or more toxicities were reported within the first cycle of therapy. This is consistent with 10	  
previous studies that have shown that toxicities do not occur in isolation and are likely to be 11	  
biologically linked, perhaps through systemic cytokine production and release [26, 27]. In regards to 12	  
potential underpinning mechanisms between TNF and nausea and vomiting, this has not been studied 13	  
directly to date. However, in a phase I clinical trial of systemic TNF for solid tumors, nausea and 14	  
vomiting were of the most common toxicities, indicating a possible relationship between TNF levels 15	  
and this symptom [28]. In the present study, toxicity that developed only within the first 4 weeks of 16	  
treatment was included in analysis. As such, late onset radiation esophagitis may have been under 17	  
reported. This is a serious and dose-limiting toxicity for patients receiving thoracic radiation and is 18	  
associated with fibrotic changes that can present months to years following completion of 19	  
radiotherapy [29].  Acute radiation esophagitis has also been reported to occur during or just after the 20	  
completion of therapy and is highly dose-dependent [15], although the etiology is difficult to separate 21	  
from mucosal injury in other areas including the oral cavity and pharynx.  In response to this, previous 22	  
clinical trials have classified mucositis and acute esophagitis as a single entity [30,31] and shown 23	  
incidence rates similar to that seen in our study.   24	  
In our cohort of patients we found that pre-therapy elevated expression of pro-inflammatory genes 25	  
was associated with toxicity.  In particular, TNF was consistently elevated in patients that experienced 26	  
severe CRT-induced GI toxicity. In contrast, IL1B and NFKB1 were only elevated in the PCR array.  27	  
11	  
	  
PCR arrays were not conducted on the full cohort of patients , and the PCR array cohort was more 1	  
homogeneous than the full cohort because it only included males and a maximum of grade 1 toxicity 2	  
in the non-toxic group.  This may have led to a much wider separation in gene expression signatures 3	  
compared to the full cohort, which included females and grade 2 toxicity.  The observation of elevated 4	  
TNF supports findings by other investigators that have shown evidence of inflammatory markers as 5	  
risk predictors of treatment toxicity.  An association between the TNFA-1031T>C promoter 6	  
polymorphism, which is known to alter protein levels, and toxicity has been shown in Japanese 7	  
patients with esophageal cancer treated by CRT [13].  Investigators used a multivariate logistic 8	  
regression model to show that TNFA-1031T>C was significantly associated with oral mucositis and 9	  
this was the only significant independent risk factor identified.  Furthermore, patients heterozygous 10	  
for the TNFA-308G>A promoter polymorphism (known to increase expression of TNF-α) are at 11	  
significantly increased risk of severe toxicity affecting the mucosa following myeloablative 12	  
chemotherapy for HSCT [23].  In a study investigating genetic variation and risk of radiation 13	  
esophagitis in patients with non-small cell lung cancer, investigators identified the TNFA-857C>T 14	  
promoter polymorphism [24].  They found no significant differences between patients who developed 15	  
severe esophagitis and those who did not with regard to age, sex, smoking status, histology, clinical 16	  
stage and performance status.  In addition, previous research using samples collected from patients 17	  
with esophageal cancer treated with neoadjuvant chemotherapy, found monocytes with increased 18	  
capacity to secrete IL-12 and reduced IL-10 in response to lipopolysaccharide and interferon were 19	  
predictive of severe mucositis [32]. Collectively, these studies strongly support a role for elevated 20	  
TNF signaling as an important risk factor for CRT-induced GI toxicity.  However, it is important to 21	  
note the limitation of our current approach, which is the use of housekeeping genes for normalization 22	  
of data.  Future research will utilize a quantitative approach to improve accuracy and reproducibility 23	  
of results. 24	  
With regard to toxicity severity, grade ≥ 3 GI toxicities are reported to occur at a rate of anywhere 25	  
between 6 and 50% [3, 33-37], showing high inter-study and interpatient variability.  This may be 26	  
partially explained by the different regimens in use as well as the difficulty of assessing GI toxicities, 27	  
12	  
	  
which rely on the subjective description given by the patients and lack of quantitative tests for the 1	  
assessment of nausea, vomiting and diarrhea. There is currently no effective tool to stratify patients 2	  
for toxicity, and traditional treatment-based and patient-based factors are poor predictors [38]. Our 3	  
study found no associations between toxicity and age, sex, tumor histology, stage or treatment, which 4	  
is in line with previous studies [39-41].  However it should be noted that we did not look specifically 5	  
for associations between gene expression and these same variables separate to toxicity.  Given that 6	  
gene expression profiles have been used previously to generate predictive models of patient response 7	  
to CRT [42-44], this approach may be equally able to generate predictive models of toxicity from 8	  
CRT in patients. We chose the arbitrary cut off of CTCAE grade 3 toxicity to categorize patients as 9	  
toxic.  As such, the non-toxic group contained a mixture of no (grade 0), mild (grade 1) and moderate 10	  
(grade 2) GI toxicities, which may have caused reduced separation in marker expression.  Comparison 11	  
of our findings to other studies is also made difficult by the use of different toxicity scoring systems 12	  
and variation in group allocation thresholds.  13	  
Finally, we found no association between severe GI toxicity and response to CRT, although our study 14	  
size was underpowered to detect this.  The roughly 30% complete or near complete response rate seen 15	  
in our study is in line with previous clinical studies for esophageal cancer [45].  Our findings are in 16	  
contrast to a recent study that found acute toxicity may be a significant prognostic factor for response 17	  
and overall survival in patients with esophageal cancer [41]. Investigators showed that patients with 18	  
worsening odynophagia (described as mucositis of the esophagus) during CRT were more likely to 19	  
have tumor regression grade 1 and improved 5-year survival.  Importantly, this was the only 20	  
independent prognostic factor identified.  As such, there is merit in investigating the relationship 21	  
between acute tissue toxicity and tumor response in clinical trials to help delineate supportive care 22	  
approaches for patients with esophageal cancer.   23	  
In conclusion, this study has provided supporting evidence for TNF as a gene associated with GI 24	  
toxicity risk.  Use of molecular, blood-based biomarkers such as gene expression is a quick and non-25	  
invasive method for obtaining toxicity risk information and could be easily translated to a diagnostic 26	  
13	  
	  
tool. Although these initial results are positive, the interpretation of our findings is limited given the 1	  
small sample size of this pilot study which will require confirmation in a larger cohort.    2	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Figure notes 1	  
Figure 1. Study workflow.   2	  
 3	  
Figure 2. Relative mRNA expression in toxic vs non-toxic samples.  Data shown is fold difference in 4	  
expression where the average non-toxic delta CT value was used as the comparator. Box and whisker 5	  
plot gives median with range for TNF, NFKB1 and IL1B.  Only TNF was found to be elevated in the 6	  
toxic group. 7	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